FDA Approves Exkivity (mobocertinib) for EGFR Exon20 Insertion+ Non-Small Cell Lung Cancer (NSCLC)

By | September 16, 2021

[unable to retrieve full-text content]OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE) September 15, 2021 –Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has approved Exkivity…
Drugs.com – New Drug Approvals

Read More:  Why is keto a bad diet